A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP

Inclusion Criteria:

1. Written and signed informed consent obtained before any protocol specific assessmentis performed.

2. Male or female, ages 18 years or older.

3. Has at least 3 of the following symptoms:

• Cough

• Production of purulent sputum

• Dyspnea (shortness of breath)

• Chest pain

4. Has at least 2 of the following abnormal vital signs:

• Fever or hypothermia documented by the investigator (temperature > 38.0°C or < 36.0°C)

• Hypotension with systolic blood pressure (SBP) < 90 mmHg

• Heart rate (HR) > 90 beats per minute (bpm)

• Respiratory rate (RR) > 20 breaths/minute

Exclusion Criteria:

1. Has received antibacterial treatment >24hr within the 72hr window prior torandomization. Subjects may be eligible despite prior antibacterial therapy if they had beentreated with short action time antimicrobial for ≤24h, or if they have received > 48hours of prior systemic antibacterial therapy for the current episode of CABP withunequivocal clinical evidence of treatment failure.

2. Is known or suspected to have CABP caused by a pathogen that may be resistant toeither test article (eg, Klebsiella pneumoniae, Pseudomonas aeruginosa, Pneumocystisjiroveci, obligate anaerobes, mycobacteria, fungal pathogens).

3. Suspected or confirmed empyema (a parapneumonic pleural effusion is not an exclusioncriteria) or lung abscess.